Nonalcoholic Steatohepatitis (NASH) is a liver disease caused due to the presence of fatty, inflamed and damaged liver, normally found in non alcoholic people. The progression of alcoholic disease is rigorous and may lead to terminal stage of liver diseases such as cirrhosis, liver failure, and hepatocellular cancer in rare cases. Nonalcoholic Steatohepatitis (NASH) is affecting approximately 2-5% of Americans. In addition, 10-20% of Americans are experiencing “fatty liver” disease that is somewhat similar to NAHS.
Increase in prevalence of diabetes and obesity has fueled the market for NAHS therapeutics, especially in developed economies. The people from developed economies are prone to this disease due to irregular eating habits. However, efficient alternative technologies such as anti-fibrotic and anti-diabetic therapies are giving tough competition to NAHS therapies/treatments.
Nonalcoholic Steatohepatitis Therapeutics Analysis
The global Nonalcoholic Steatohepatitis market by therapeutics is segmented into GFT505, Obeticholic Acid (INT-747), Simtuzumab Liraglutide (Victoza)
Nonalcoholic Steatohepatitis Geography Analysis
The global Nonalcoholic Steatohepatitis market by geography is categorized into four segments such as North America, Europe, Asia-Pacific and LAMEA (Latin America, Middle East, and Africa). The North America and European countries are prone to this disease. These two regions are expected to share more than 50% of market share due to the irregular food habits and unhealthy lifestyle among the people in these regions.
Competitive Landscape (Drugs)
Competitive landscape for this report is analyzed for the drugs available/used in the treatment of Nonalcoholic Steatohepatitis. The manufacturers engaged in manufacturing of these drugs are expected to adopt the NASH technologies.
High Level Analysis
The Nonalcoholic Steatohepatitis market is an emerging field of therapeutics. The market is facing challenges due to stringent regulations. However, these regulations are strategically dealt in this report and more emphasis is given on the commercial polices available for the Nonalcoholic Steatohepatitis therapeutics. The clinical trials conducted for the development of novel therapies are critically analyzed so that key players competing in this market can take strategic decisions. The market dynamics of Nonalcoholic Steatohepatitis market is showing the impact of the drivers over the restraints and also focusing on the enormous opportunities available in the market.
This report gives a detailed analysis of drivers and factors limiting market expansion
Porter’s five forces and SWOT analysis for drug and therapeutics discussed would help in making strategic decisions
Strategies adopted for the commercialization of therapies are dealt to give a deep dive intelligence on top contenders in the market
Micro level analysis is conducted based on therapeutics and geographies
Identification of key investment pockets for therapies used in the NAHS Market
Reason for Doing Study
Increase in prevalence and lack in right type of therapies are promoting the companies to seek the novel opportunities in this market. The study conducted by Allied Market Research is mainly emphasizing on the trends and potential available for the commercialization of therapeutics. Moreover, rise in incidence of chronic liver diseases is also igniting the growth of NAHS therapeutics market. Research companies are in search of novel therapeutics for NAHS as there are very few therapies available on liver diseases. The report in this case, is analyzing key therapeutics drugs available in commercial market in order to reveal the market opportunities for the commercialization of therapeutic drugs.
The Global Nonalcoholic Steatohepatitis market is segmented into therapeutics, and geography.
Market by Therapeutics
Obeticholic Acid (INT-747)
Simtuzumab Liraglutide (Victoza)
Market by Geography